Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 2:25 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Open Bite Clear all
Completed Not applicable Interventional

Sapphire 3 CTO Study

NCT06358508
View directory record Official record
Conditions
Coronary Artery Disease, Coronary Disease, Myocardial Ischemia, Heart Diseases, Arteriosclerosis, Cardiovascular Diseases, Chronic Total Occlusion, Chronic Total Occlusion of Coronary Artery
Interventions
Sapphire 3 Coronary Dilatation Catheter
Device
Lead sponsor
OrbusNeich
Industry
Eligibility
18 Years and older
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
12
States / cities
Stanford, California • Torrance, California • Atlanta, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2026 · Synced Jul 22, 2026, 2:25 PM EDT
Terminated Phase 4 Interventional Results available

Significance of Antibodies to Heparin/Platelet Factor 4 Complex in Vein Graft Patency and Potential Role of Argatroban for Prevention of Vein Graft Occlusion

NCT01246011
View directory record Official record
Conditions
Coronary Artery Bypass Graft Surgery, Presence of Heparin/Platelet Factor 4 Antibody
Interventions
Argatroban and warfarin
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 16, 2017 · Synced Jul 22, 2026, 2:25 PM EDT
Completed No phase listed Observational

Saphenous Vein Allografts for Coronary Bypass

NCT01386021
View directory record Official record
Conditions
Coronary Artery Disease, Occlusion of Artery
Interventions
Not listed
Lead sponsor
CryoLife, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 20, 2011 · Synced Jul 22, 2026, 2:25 PM EDT
Completed Phase 2 Interventional

Safety and Proof of Concept Study of ANXV (Annexin A5) in Patients With Retinal Vein Occlusion

NCT05532735
View directory record Official record
Conditions
Retinal Vein Occlusion
Interventions
ANXV
Biological
Lead sponsor
Annexin Pharmaceuticals AB
Industry
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
7
States / cities
West Monroe, Louisiana • Hagerstown, Maryland • Tulsa, Oklahoma + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 10, 2024 · Synced Jul 22, 2026, 2:25 PM EDT
Not listed Phase 4 Interventional

ShuntCheck-Micro-Pumper Pediatric Clinical Outcomes Study

NCT01881711
View directory record Official record
Conditions
Suspected CSF Shunt Obstruction
Interventions
ShuntCheck-Micro-Pumper (SCMP), Imaging
Device
Lead sponsor
NeuroDx Development
Industry
Eligibility
35 Months to 29 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
11
States / cities
Wilmington, Delaware • Washington D.C., District of Columbia • Chicago, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2015 · Synced Jul 22, 2026, 2:25 PM EDT
Terminated Phase 2 Interventional

Treatment of Rubeosis Iridis With Open-Label Anecortave Acetate Sterile Suspension ( 15 mg.).

NCT00211471
View directory record Official record
Conditions
Severe Diabetic Retinopathy, Central Retinal Vein Occlusion, Chronic Inflammation, Infectious Diseases
Interventions
anecortave acetate
Drug
Lead sponsor
Manhattan Eye, Ear & Throat Hospital
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 6, 2007 · Synced Jul 22, 2026, 2:25 PM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Development of an Intrauterine Pressure Threshold to Confirm Tubal Occlusion

NCT04071392
View directory record Official record
Conditions
Sterilization, Female, Fallopian Tube Occlusion
Interventions
Hysterosalpingogram (HSG)
Procedure
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Dec 9, 2019 · Synced Jul 22, 2026, 2:25 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Study to Evaluate the Effect of Funk It Cycle Bites on PMS

NCT05900024
View directory record Official record
Conditions
Premenstrual Syndrome
Interventions
Funk It Cycle Bites
Other
Lead sponsor
Funk It Wellness
Industry
Eligibility
18 Years to 40 Years · Female only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Feb 28, 2024 · Synced Jul 22, 2026, 2:25 PM EDT
Completed Phase 2 Interventional Results available

Cantharidin and Occlusion in Verruca Epithelium

NCT03487549
View directory record Official record
Conditions
Common Wart, Warts Hand, Warts, Papillomavirus Infections, DNA Virus Infections, Skin Diseases, Viral, Skin Diseases, Infectious, Skin Diseases, Virus Diseases, Tumor Virus Infections, Verruca Vulgaris, Verruca
Interventions
VP-102 Cantharidin, topical film forming solution
Combination Product
Lead sponsor
Verrica Pharmaceuticals Inc.
Industry
Eligibility
2 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
5
States / cities
Little Rock, Arkansas • Jacksonville, Florida • Plainfield, Indiana + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 26, 2024 · Synced Jul 22, 2026, 2:25 PM EDT
Completed Phase 2 Interventional

Heparin Versus Lepirudin Flushes in Preventing Blockage of Venous Access Devices

NCT00039767
View directory record Official record
Conditions
Thrombosis
Interventions
Lepirudin
Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
Not listed
Enrollment
340 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Jul 22, 2026, 2:25 PM EDT
Completed Phase 3 Interventional Results available

Aggressive Cholesterol Therapy to Inhibit Vein Graft Events After CABG (ACTIVE Trial)

NCT01528709
View directory record Official record
Conditions
Saphenous Vein Graft Disease
Interventions
Atorvastatin 80 mg daily, Atorvastatin 10 mg daily
Drug
Lead sponsor
Boca Raton Regional Hospital
Other
Eligibility
18 Years and older
Enrollment
173 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Boca Raton, Florida
Source: ClinicalTrials.gov public record
Updated Sep 6, 2018 · Synced Jul 22, 2026, 2:25 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

IOA Preventing Occlusal Changes With MAD Use

NCT07103941
View directory record Official record
Conditions
Sleep Related Breathing Disorder, Snoring, Obstructive Sleep Apnea (OSA), Open Bite, Occlusal Changes, Tooth Migration, Posterior Open Bite
Interventions
AM Aligner, Exercise
Device · Behavioral
Lead sponsor
Isabel Moreno Hay
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated May 17, 2026 · Synced Jul 22, 2026, 2:25 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Ranibizumab (Lucentis) for Macular Edema Secondary to Vein Occlusions

NCT00407355
View directory record Official record
Conditions
Macular Edema, Retinal Vein Occlusion
Interventions
Intravitreal injection of ranibizumab .3 dose, Intravitreal injection of Ranibizumab .5 dose
Drug
Lead sponsor
Peter A Campochiaro, MD
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 3, 2013 · Synced Jul 22, 2026, 2:25 PM EDT
Completed Phase 1 Interventional

Lucentis for Macular Edema Associated With Central Retinal Vein Occlusion

NCT01028248
View directory record Official record
Conditions
Central Retinal Vein Occlusion
Interventions
Ranibizumab (Lucentis)
Drug
Lead sponsor
California Retina Consultants
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
3
States / cities
Bakersfield, California • Santa Barbara, California • Santa Maria, California
Source: ClinicalTrials.gov public record
Updated Dec 11, 2013 · Synced Jul 22, 2026, 2:25 PM EDT
Completed Phase 2 Interventional

A Clinical Study to Assess the Safety of PEG-Hirudin (SPP200) Compared to Heparin in Patients Who Are on Haemodialysis

NCT00074620
View directory record Official record
Conditions
Chronic Kidney Failure, Vascular Graft Occlusion
Interventions
PEG-hirudin
Drug
Lead sponsor
Speedel Pharma Ltd.
Industry
Eligibility
21 Years to 75 Years
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 4, 2007 · Synced Jul 22, 2026, 2:25 PM EDT
Completed No phase listed Observational

Oxidative Stress and Hemodialysis Access Failure

NCT00410449
View directory record Official record
Conditions
End Stage Renal Disease, Hemodialysis
Interventions
Alpha tocopherol
Drug
Lead sponsor
National Institute of Environmental Health Sciences (NIEHS)
NIH
Eligibility
21 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2004
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 5, 2015 · Synced Jul 22, 2026, 2:25 PM EDT
Terminated Phase 4 Interventional Results available

Maintaining Patency in BioFlo Implanted Port Catheters With Saline Only Flushes

NCT02923830
View directory record Official record
Conditions
Obstruction; Catheter, Infusion Catheter (Vascular), Catheter; Complications (Indwelling Catheter)
Interventions
Heparinized saline catheter flush, Saline-only catheter flush
Other · Drug
Lead sponsor
TriHealth Inc.
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
6
States / cities
Cincinnati, Ohio • Hamilton, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 10, 2019 · Synced Jul 22, 2026, 2:25 PM EDT
Completed Not applicable Interventional Results available

The ShortCut™ Continued Access Study Protocol

NCT06211296
View directory record Official record
Conditions
Valve-in-valve Procedures, Aortic Stenosis, Coronary; Obstruction
Interventions
Shortcut
Device
Lead sponsor
Pi-cardia
Industry
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
4
States / cities
Thousand Oaks, California • Morristown, New Jersey • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Jul 22, 2026, 2:25 PM EDT
Suspended Not applicable Interventional

Compassionate-Use of 4% T-EDTA Lock Solution for Central Venous Lines of Pediatric PN Patients

NCT04559334
View directory record Official record
Conditions
Central Line Complication, Central Line-associated Bloodstream Infection (CLABSI)
Interventions
Tetrasodium EDTA Catheter Lock Solution
Device
Lead sponsor
Boston Children's Hospital
Other
Eligibility
3 Months to 18 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Jul 22, 2026, 2:25 PM EDT
Completed Not applicable Interventional

A Prospective, Multi-Center, Pivotal Study to Evaluate the Safety and Effectiveness of the NovaCross™ Micro-catheter in Facilitating Crossing Chronic Total Occlusion (CTO) Coronary Lesions

NCT02477579
View directory record Official record
Conditions
Chronic Total Occlusion of Coronary Artery
Interventions
NovaCross
Device
Lead sponsor
Nitiloop Ltd.
Industry
Eligibility
18 Years to 80 Years
Enrollment
145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
4
States / cities
Little Rock, Arkansas • Naperville, Illinois • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 16, 2017 · Synced Jul 22, 2026, 2:25 PM EDT
Completed Phase 4 Interventional Results available

Widefield Angiography Guided Targeted-retinal Photocoagulation Combined With Anti VEgf Intravitreal Injections for the Treatment of Ischemic Central Retinal Vein Occlusion, Hemi Retinal Vein Occlusion, and Branch Retinal Vein Occlusion

NCT01710839
View directory record Official record
Conditions
Central Retinal, Hemi Retinal & Brach Retinal Vein Occlusions
Interventions
0.5mg Ranibizumab, Targeted Pan Retinal Photocoagulation
Drug · Procedure
Lead sponsor
Charles C Wykoff, PhD, MD
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
3
States / cities
Houston, Texas • Katy, Texas • The Woodlands, Texas
Source: ClinicalTrials.gov public record
Updated Sep 7, 2017 · Synced Jul 22, 2026, 2:25 PM EDT
Recruiting Not applicable Interventional

Assessment of Tubal Occlusion During Minimally Invasive Myomectomy

NCT06988774
View directory record Official record
Conditions
Fallopian Tube Patency Tests, Fibroid/Myoma (Uterus/Cervix), Myomectomy, Fallopian Tube Disease
Interventions
chromopertubation
Procedure
Lead sponsor
Medstar Health Research Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jun 28, 2025 · Synced Jul 22, 2026, 2:25 PM EDT
Completed Phase 2 Interventional Results available

A Comparison of Crotalinae Equine Immune F(ab)2 Antivenom (Anavip) and Crotalidae Polyvalent Immune Fab,

NCT00868309
View directory record Official record
Conditions
Snake Bite, Blood Coagulation Disorders
Interventions
Anavip, CroFab
Biological
Lead sponsor
Instituto Bioclon S.A. de C.V.
Industry
Eligibility
18 Years to 70 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Apr 17, 2016 · Synced Jul 22, 2026, 2:25 PM EDT
Completed Not applicable Interventional Results available

Maintaining Patency in Implanted Port Catheters

NCT02354118
View directory record Official record
Conditions
Obstruction; Catheter, Infusion Catheter (Vascular), Catheter; Complications (Indwelling Catheter)
Interventions
Heparinized saline catheter flush, Saline-only catheter flush
Other
Lead sponsor
TriHealth Inc.
Other
Eligibility
18 Years and older
Enrollment
436 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
8
States / cities
Cincinnati, Ohio • Hamilton, Ohio • Oxford, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 11, 2022 · Synced Jul 22, 2026, 2:25 PM EDT